Via Falloppio, 61 - PADOVA
8.30-12.30 / 15.00-19.00
Sabato pomeriggio chiuso
Libreria medica internazionale
0,00 €
Essential Guide to Blood Coagulation, 2nd Edition
Antovic, Blombäck
54,00 €
I prezzi indicati possono subire variazioni poiché soggetti all'oscillazione dei cambi delle valute e/o agli aggiornamenti effettuati dagli Editori.

Thrombotic and bleeding disorders affect at least 10 million people in the US alone. There has also been a great deal of concern over travel-related deep vein thrombosis and therefore much more interest and research into the field of blood clotting. This new and concise practical guide will cover all the essentials one needs to know when managing thrombotic and bleeding disorders. The field of haematology is undergoing major advances in thrombosis research, including significant additions to recommended treatment protocols. The Essential Guide to Coagulation will distil the most clinically, up-to-date and relevant material from the literature for all those working in the field.

Faced with a bleeding patient, it may be difficult to discern whether blood loss is due to a local factor or secondary to an underlying haemostatic defect. There are a range of simple and specialized laboratory texts which can be performed to further define the cause of bleeding in a patient. Since the first edition there have been many developments in the field including many new anticoagulant drugs. These new classes of "direct thrombin inhibitors" slow the coagulation cascade by directly binding to thrombin, a clotting factor essential in the clotting process. If thrombin is blocked, clot formation is delayed. A key component of this guide will be the latest treatment strategies available for patients.

  • Table of Contents

List of contributors, x

Preface, xii

Abbreviations, xiii


1 Schematic presentation of the hemostatic system, 3
Nils Egberg

2 Proposals for sampling instructions, 6
Margareta Blombäck and Nils Egberg

Points to note prior to sampling, 6

Sampling time and patient preparation, 7

Referrals for coagulation analyses, 8

Sampling, 8

Technique, 9

For DNA investigation (genetic analyses), 10

3 Laboratory investigations, 11
Jovan P. Antovic, Liselotte Onelöv, and Nils Egberg

Nomenclature, 11

Reference intervals for laboratory investigations, 13

Screening analyses, 13

Special analyses, 20

Markers of coagulation activation (hypercoagulation markers), 29

DNA analyses, 29

Global hemostatic assays and bedside methods, 31

Useful components in research studies, 32

Platelet-activating predictors, 35


4 Hereditary bleeding disorders, 41
Margareta Holmström and Lars Göran Lundberg

General remarks about hemophilia A and B, 41

General remarks about von Willebrand disease, 42

Factor concentrates used for treatment of hemophilia A and B and VWD in Sweden in 2012, 43

Treatment strategy in severe forms of hemophilia and VWD, 44

Recommendations for desired initial plasma concentrations at different types of bleedings, 45

Surgery in patients with bleeding disorders, 47

Tooth extraction in a hemophilia patient, 47

Caution in patients with bleeding disorders, 48

Treatment principles for different types of bleeding disorders (severe, moderate, and milder forms of hemostatic defects), 49

Rare bleeding disorders, 51

Blood sampling in bleeding disorders, 54

Bleeding risk charts, 54

5 Critical bleeding, 56
Maria Bruzelius, Anna Ågren, and Hans Johnsson

Introduction, 56

Defi nition of massive bleeding, 56

Transfusion coagulopathy, 56

Recommendations to obtain optimal hemostasis, 57

Choice of plasma, 58

Local procedures, 59

Additional treatment, 59

Fibrinogen concentrate, 59

Prothrombin-complex concentrate (PCC), 59

Recombinant factor VIIa, 59

Concentrates of other coagulation factors, 60

Cryoprecipitates, 60

Tranexamic acid, 60

Desmopressin, 60

Local hemostatic drugs, 60

Complicating factors, 61

Ongoing treatment with antiplatelet, and anticoagulant drugs, 61

6 Investigation of increased bleeding tendency, 62
Margareta Holmström and Lars Göran Lundberg

Introduction, 62

Diagnosis, 62

Reasons for pathologic screening analyses and further actions, 64

Causes of thrombocytopenia, 64

Causes of prolonged activated partial thromboplastin time, 65

Causes of elevated PT(INR), 66

Investigation of bleeding tendency: practical aspects, 66


7 Venous thrombosis and pulmonary embolism, 71
Anders Carlsson

Introduction, 71

Venous thrombosis, 72

Pulmonary embolism, 75

Primary prophylaxis against VTE, 91

8 Investigations of thromboembolic tendency, 94
Margareta Holmström

Introduction, 94

Venous thromboembolism, 95

Arterial thromboembolism, 96

Disseminated intravascular coagulation, 96

9 Heart disease, 97
Håkan Wallen and Rickard Linder

Ischemic heart disease, 97

Atrial fi brillation, 102

Cardiac valve prosthesis, 103

New oral anticoagulants in the treatment of heart disease, 104

10 Antiplatelet drug therapy and reversal of its effects, 105
Håkan Wallen, Hans Johnsson, and Bo-Michael Bellander

Introduction, 105

ASA, 105

ADP (P2Y12) receptor antagonists, 106

GPIIb/IIIa receptor antagonists, 106

Phosphodiesterase inhibitors and other antiplatelet compounds, 108

Combined antithrombotic treatment, 108

Benefi t–risk assessment, 108

Platelet transfusion, 109

11 New oral anticoagulants: Focus on currently approved oral factor Xa and Thrombin inhibitors, 111
Rickard E. Malmström and Hans Johnsson

Clinical pharmacology of NOACs, 111

Possibility of and need for therapeutic monitoring of NOACs, 114

Clinical aspects of NOACs, 114

Results of clinical trials, 116

Some characteristics of the individual NOACs, 118

Considerations to be taken when using NOACs in some emergency situations

12 Stroke and transient ischemic attack, 121
Nils Wahlgren and Mia von Euler

Antithrombotic secondary stroke prevention, 121

Atrial fi brillation and TIA or stroke, 122

Thrombolysis in stroke, 122

Cerebral venous thrombosis and dissection of precerebral arteries, 123

Recurrent TIA, 124

Prophylactic treatment against DVT and PE, 124

13 Peripheral artery surgery, 125
Jesper Swedenborg

Prophylaxis against reocclusion in peripheral vascular surgery or percutaneous transluminal angioplasty (PTA), 125

Peri- and postoperative treatment, 125

Thrombolysis in acute ischemia, 126


14 Hemostasis in obstetrics and gynecology, 129
Katarina Bremme

Introduction, 129

Thrombosis during pregnancy, 131

Heart disease: treatment of women with mechanical heart valve prostheses, 139

Thromboprophylaxis in obstetrics and gynecology, 140

Blood sampling in children of women with severe forms of thrombophilia, 148

Obstetric epidural/spinal analgesia (anesthesia), 148

Complications during pregnancy, 150

Postpartum bleeding, 155

Thromboprophylaxis in legal and spontaneous abortions, 156

Thromboprophylaxis in gynecologic surgery, 156

Investigation prior to artifi cial insemination (IVF), 160

Investigation in repeated miscarriages, 160

Investigation in menorrhagia (for treatment see Chapter 4), 161

15 Hemostasis in children, 162
Susanna Ranta and Pia Petrini

Introduction, 162

Bleeding disorders in children, 166

Thromboembolic disorders in children, 172

16 Emergency conditions associated with coagulation: DIC, HIT and TTP/HUS, 182
Jovan P. Antovic and Margareta Holmström

Disseminated intravascular coagulation, 182

Heparin-induced thrombocytopenia, 188

Thrombotic microangiopathies, 190

Index, 191



Non ci sono recensioni

Aggiungi la tua recensione

Ultimi prodotti